Talabostat

Abstract

Talabostat mesilate is an orally active, specific inhibitor of dipeptidyl peptidases, including tumor-associated fibroblast activation protein. However, by an independent mechanism, talabostat also stimulates the upregulation of cytokines and chemokines to engender a tumor-specific host immune response, thus giving it a unique dual mechanism of action. In clinical trials, talabostat has demonstrated significant activity, including achieving complete responses in patients with non-small-cell lung cancer and malignant melanoma.

Keywords::

• CD26/dipeptidyl peptidase IV
• fibroblast activation protein
• metastatic melanoma
• non-Hodgkin's lymphoma
• non-small cell lung cancer
• talabostat
• tumor stroma

Acknowledgements

The author wishes to thank JF Tomera, Director of Clinical Development at Point Therapeutics of Boston, Massachusetts for assimilating details contained within the manuscript.

Notes